Anavex Life Sciences Strengthens Board of Directors

NEW YORK – February 13, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Peter Donhauser, D.O.…

BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”

Event:   BIO CEO & Investor Conference 2017 Date/Time:      Tuesday, February 14, 2017 from 2:30 p.m. to 3:25 p.m. Eastern Time Location:         The Waldorf Astoria Hotel in New York, NY https://www.bio.org/events/bio-ceo-investor-conference Christopher U. Missling, PhD, President and Chief Executive Officer will participate on the panel titled “Designing Clinical Trials in a 21st Century Cures…

Anavex Life Sciences’ CEO Joins BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”

NEW YORK – February 9, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President…

Anavex Reports Fiscal First Quarter 2017 Financial Results

NEW YORK – February 7, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three months…